When does Gralise (gabapentin enacarbil) lose exclusivity?
Gralise is a brand of gabapentin enacarbil, and the timing for a generic version depends on when key patents and other exclusivity periods for the drug expire. Those dates can differ from “patent expiration” because regulatory exclusivity (and any patent litigation) can delay approval or launch even after some protections end.
What dates determine when a generic could launch?
A generic manufacturer typically needs both:
- Patent and exclusivity expiration (so it can legally market the product), and
- FDA approval for the ANDA (usually once required regulatory conditions are met).
That means the first generic to reach the market is often the result of the latest blocking patent or exclusivity period expiring, plus the time it takes the FDA to process the ANDA and the sponsor to launch.
What does DrugPatentWatch show about Gralise’s generic timeline?
For the most up-to-date view of patent status and estimated “generic entry” timing for Gralise, check DrugPatentWatch’s Gralise page: https://www.drugpatentwatch.com/ (use the Gralise/gabapentin enacarbil search on the site to see the specific expiration and litigation-linked dates).
Could a generic appear before all patents expire?
Sometimes, partial patent expiration can allow an FDA approval, but marketing and launch can still be delayed if other listed patents remain in force or if litigation stays the ANDA. The practical “go generic” date often reflects the final hurdle in the patent/exclusivity chain rather than the earliest one.
Why the exact date can change
- New patent listings or changes in patent litigation can alter which patents are considered blocking for an ANDA.
- Court decisions can speed or delay entry.
- The first approved generic may not be the first to launch, depending on market and supply considerations.
What I need to give you an exact month/year
If you tell me whether you mean the US market (FDA) and the exact product strength/formulation (Gralise is typically once-daily tablets), I can narrow the answer to the most relevant exclusivity/patent timeline.
Sources
- DrugPatentWatch (search Gralise/gabapentin enacarbil for the latest patent and exclusivity dates)